Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual depigmented polymerized Phleum pratense allergen immunotherapy in allergic rhinoconjunctivitis and/or asthma
2006-001437-18Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Jan 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of depigmented polymerized phleum pratense pollen extract in allergic rhinoconjunctivitis (ARC), asthma and grass pollen allergy, sponsored by LETI Pharma. Primary endpoint: Total symptom score. Started Jan 2007; status: completed.
02
Drugs
depigmented polymerized phleum pratense pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)asthmagrass pollen allergy
Beyond the preview
Go deeper on 2006-001437-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001437-18.